190 related articles for article (PubMed ID: 28869310)
1. Chromatographic approaches for the characterization and quality control of therapeutic oligonucleotide impurities.
El Zahar NM; Magdy N; El-Kosasy AM; Bartlett MG
Biomed Chromatogr; 2018 Jan; 32(1):. PubMed ID: 28869310
[TBL] [Abstract][Full Text] [Related]
2. THERAPEUTIC OLIGONUCLEOTIDES, IMPURITIES, DEGRADANTS, AND THEIR CHARACTERIZATION BY MASS SPECTROMETRY.
Pourshahian S
Mass Spectrom Rev; 2021 Mar; 40(2):75-109. PubMed ID: 31840864
[TBL] [Abstract][Full Text] [Related]
3. Advantages of ion-exchange chromatography for oligonucleotide analysis.
Cook K; Thayer J
Bioanalysis; 2011 May; 3(10):1109-20. PubMed ID: 21585306
[TBL] [Abstract][Full Text] [Related]
4. Analytical techniques for characterizing diastereomers of phosphorothioated oligonucleotides.
Chen T; Tang S; Fu Y; Napolitano JG; Zhang K
J Chromatogr A; 2022 Aug; 1678():463349. PubMed ID: 35908512
[TBL] [Abstract][Full Text] [Related]
5. Degradation product characterization of therapeutic oligonucleotides using liquid chromatography mass spectrometry.
Elzahar NM; Magdy N; El-Kosasy AM; Bartlett MG
Anal Bioanal Chem; 2018 May; 410(14):3375-3384. PubMed ID: 29654340
[TBL] [Abstract][Full Text] [Related]
6. Semi-quantitative determination of co-eluting impurities in oligonucleotide drugs using ion-pair reversed-phase liquid chromatography mass spectrometry.
Roussis SG; Cedillo I; Rentel C
J Chromatogr A; 2019 Jan; 1584():106-114. PubMed ID: 30473112
[TBL] [Abstract][Full Text] [Related]
7. Forced degradation and impurity profiling: recent trends in analytical perspectives.
Jain D; Basniwal PK
J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
[TBL] [Abstract][Full Text] [Related]
8. Levothyroxine sodium revisited: A wholistic structural elucidation approach of new impurities via HPLC-HRMS/MS, on-line H/D exchange, NMR spectroscopy and chemical synthesis.
Ruggenthaler M; Grass J; Schuh W; Huber CG; Reischl RJ
J Pharm Biomed Anal; 2017 Feb; 135():140-152. PubMed ID: 28024262
[TBL] [Abstract][Full Text] [Related]
9. Current State of Oligonucleotide Characterization Using Liquid Chromatography-Mass Spectrometry: Insight into Critical Issues.
Sutton JM; Guimaraes GJ; Annavarapu V; van Dongen WD; Bartlett MG
J Am Soc Mass Spectrom; 2020 Sep; 31(9):1775-1782. PubMed ID: 32812756
[TBL] [Abstract][Full Text] [Related]
10. DETECTING LOW-LEVEL SYNTHESIS IMPURITIES IN MODIFIED PHOSPHOROTHIOATE OLIGONUCLEOTIDES USING LIQUID CHROMATOGRAPHY - HIGH RESOLUTION MASS SPECTROMETRY.
Nikcevic I; Wyrzykiewicz TK; Limbach PA
Int J Mass Spectrom; 2011 Jul; 304(2-3):98-104. PubMed ID: 21811394
[TBL] [Abstract][Full Text] [Related]
11. Determination of individual oligonucleotide impurities by small amine ion pair-RP HPLC MS and MS/MS: n - 1 impurities.
Roussis SG; Rodriguez AA; Rentel C
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Apr; 1169():122611. PubMed ID: 33706187
[TBL] [Abstract][Full Text] [Related]
12. Chromatographic methods for the determination of therapeutic oligonucleotides.
McGinnis AC; Chen B; Bartlett MG
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Feb; 883-884():76-94. PubMed ID: 21945211
[TBL] [Abstract][Full Text] [Related]
13. Two-dimensional sequential selective comprehensive chiral×reversed-phase liquid chromatography of synthetic phosphorothioate oligonucleotide diastereomers.
Li F; Knappe C; Carstensen N; Favorat E; Gao M; Holkenjans W; Hetzel T; Pell R; Lämmerhofer M
J Chromatogr A; 2024 Jun; 1730():465076. PubMed ID: 38879975
[TBL] [Abstract][Full Text] [Related]
14. Development of Impurity Profiling Methods Using Modern Analytical Techniques.
Ramachandra B
Crit Rev Anal Chem; 2017 Jan; 47(1):24-36. PubMed ID: 27070830
[TBL] [Abstract][Full Text] [Related]
15. Highly efficient, selective, sensitive and stability indicating RP-HPLC-UV method for the quantitative determination of potential impurities and characterization of four novel impurities in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI-IT/MS/MS.
Thomas S; Bharti A; Maddhesia PK; Shandilya S; Agarwal A; Dharamvir ; Biswas S; Bhansal V; Gupta AK; Tewari PK; Mathela CS
J Pharm Biomed Anal; 2012 Mar; 61():165-75. PubMed ID: 22178334
[TBL] [Abstract][Full Text] [Related]
16. Assay, Purity, and Impurity Profile of Phosphorothioate Oligonucleotide Therapeutics by Ion Pair-HPLC-MS.
Rentel C; Gaus H; Bradley K; Luu N; Kolkey K; Mai B; Madsen M; Pearce M; Bock B; Capaldi D
Nucleic Acid Ther; 2022 Jun; 32(3):206-220. PubMed ID: 35238617
[TBL] [Abstract][Full Text] [Related]
17. Formation of oligonucleotide adducts in pharmaceutical formulations.
Krotz AH; Gaus H; Hardee GE
Pharm Dev Technol; 2005; 10(2):283-90. PubMed ID: 15926677
[TBL] [Abstract][Full Text] [Related]
18. Critical practical aspects in the application of liquid chromatography-mass spectrometric studies for the characterization of impurities and degradation products.
Narayanam M; Handa T; Sharma P; Jhajra S; Muthe PK; Dappili PK; Shah RP; Singh S
J Pharm Biomed Anal; 2014 Jan; 87():191-217. PubMed ID: 23706957
[TBL] [Abstract][Full Text] [Related]
19. Automated determination of early eluting oligonucleotide impurities using ion-pair reversed-phase liquid chromatography high resolution-mass spectrometry.
Roussis SG; Cedillo I; Rentel C
Anal Biochem; 2020 Apr; 595():113623. PubMed ID: 32067983
[TBL] [Abstract][Full Text] [Related]
20. Combining ion pairing agents for enhanced analysis of oligonucleotide therapeutics by reversed phase-ion pairing ultra performance liquid chromatography (UPLC).
Levin DS; Shepperd BT; Gruenloh CJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jun; 879(19):1587-95. PubMed ID: 21514903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
